WuXi Biologics resets Massachusetts factory timeline after redesign
After a 'redesign,' WuXi Biologics announces a new completion timeline for its Massachusetts manufacturing facility, amid ongoing US-China biopharma tensions.
WuXi Biologics
HKEX: 2269 ~$15B MCAP
WuXi Biologics (HKEX: 2269) is a leading global Contract Development and Manufacturing Organization (CDMO) providing end-to-end biologics discovery, development, and manufacturing services — including monoclonal antibodies, bispecifics, antibody-drug conjugates, and recombinant proteins — from sites in China, Ireland, the U.S., and Singapore.
Company Info
Sector:Contract Development & Manufacturing (CDMO)
Headquarters:Wuxi, Jiangsu, China
Founded:2010
Website:www.wuxibiologics.com/
Recent News
Leadership Team
Dr. Chris Chen
Chief Executive Officer
Careers & Job Openings